

Hetero launches anti-retroviral drug in India

01 March 2018 | News

The product has been approved by the Drug Controller General of India and will be marketed and distributed under the brand name 'TAFERO-EM'.



Hyderabad based Hetero Healthcare has recently launched generic anti-retroviral fixed-dose combination (FDC) of 'Emtricitabine (200mg) and Tenofovir Alafenamide (25mg) in India. The product is the first generic version of Gilead's Descovy.

The product has been approved by the Drug Controller General of India (DCGI) and will be marketed and distributed under the brand name 'TAFERO-EM'.

The medication is indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 12 years of age and older.